Collaborative Commercialization at Gilead Sciences: Resolving the Innovation Vs. Access Tradeoff Harvard Case Solution & Analysis

The case scenario handles Gilead Sciences; a bio-pharmaceutical organization along with numerous FDA gave consent to HIV/AIDS drugs. In the year 2006, the business launched the Gilead Access Program to improve accessibility to HIV/AIDS drugs in developing countries. In India, which at the same time happened to be the largest manufacturer of generic drugs, Gilead signed a voluntary licensing agreement for its drug, Viread, with 13 firms.By year 2011, Mylan (formerly known as Matrix Laboratories), among the 13 Indian firms, had materialized as the top supplier for Viread, with two-thirds of the global market. In order to hasten its market reach, Gilead needed to expand the extent of the agreement with four leading Indian businesses, comprising Mylan. Gregg Alton, the Executive Vice President for the Corporate and Medical Affairs must choose how he had assured his partners to come on board and the way to execute the agreement.

PUBLICATION DATE: June 30, 2013 PRODUCT #: ISB025-PDF-ENG

This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP

Share This

SALE SALE

Save Up To

30%

IN ONLINE CASE STUDY

FOR FREE CASES AND PROJECTS INCLUDING EXCITING DEALS PLEASE REGISTER YOURSELF !!

Register now and save up to 30%.